@article{MTMT:34726620,
	title = {Durvalumab ± Tremelimumab plus Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden},
	url = {https://m2.mtmt.hu/api/publication/34726620},
	author = {Paz-Ares, Luis and Garassino, Marina Chiara and Chen, Yuanbin and Reinmuth, Niels and Hotta, Katsuyuki and Poltoratskiy, Artem and Trukhin, Dmytro and Hochmair, Maximilian J. and Oezgueroglu, Mustafa and Ji, Jun Ho and Statsenko, Galina and Conev, Nikolay and Bondarenko, Igor and Havel, Libor and Losonczy, György and Xie, Mingchao and Lai, Zhongwu and Godin-Heymann, Nadia and Mann, Helen and Jiang, Haiyi and Shrestha, Yashaswi and Goldman, Jonathan W.},
	doi = {10.1158/1078-0432.CCR-23-1689},
	journal-iso = {CLIN CANCER RES},
	journal = {CLINICAL CANCER RESEARCH},
	volume = {30},
	unique-id = {34726620},
	issn = {1078-0432},
	abstract = {Purpose: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). Experimental design: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. Results: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on >= 1% tumor cells (TC), >= 1% immune cells (IC), and >= 1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47-0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 >= 1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672). Conclusions: OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset. See related commentary by Rolfo and Russo, p. 652.},
	keywords = {BLOCKADE; SURVIVAL; Genotype; monotherapy; OPEN-LABEL; ipilimumab; nivolumab; CHECKMATE 032; TMB TTMB},
	year = {2024},
	eissn = {1557-3265},
	pages = {824-835},
	orcid-numbers = {Garassino, Marina Chiara/0000-0002-3821-5598; Ji, Jun Ho/0000-0003-1730-2606; Bondarenko, Igor/0000-0002-7071-2471; Losonczy, György/0000-0002-5340-360X}
}

@article{MTMT:34441154,
	title = {Circulating apelin, IL22RA2 and VEGF in pre-capillary pulmonary hypertension},
	url = {https://m2.mtmt.hu/api/publication/34441154},
	author = {Csósza, Györgyi and Szűcs, Gergő and Rozgonyi, Zsolt Dezső and Csoma, Balázs and Losonczy, György and Müller, Veronika and Karlócai, Kristóf and Lázár, Zsófia},
	doi = {10.1556/2060.2023.00264},
	journal-iso = {PHYSIOL INT},
	journal = {PHYSIOLOGY INTERNATIONAL},
	volume = {110},
	unique-id = {34441154},
	issn = {2498-602X},
	year = {2023},
	eissn = {2677-0164},
	pages = {356-370},
	orcid-numbers = {Csósza, Györgyi/0000-0002-5510-5868; Szűcs, Gergő/0000-0002-3446-0406; Rozgonyi, Zsolt Dezső/0000-0002-6395-7139; Csoma, Balázs/0000-0002-9425-1219; Losonczy, György/0000-0002-5340-360X; Müller, Veronika/0000-0002-1398-3187; Karlócai, Kristóf/0000-0003-2162-2039; Lázár, Zsófia/0000-0003-2444-9040}
}

@article{MTMT:34314284,
	title = {Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide},
	url = {https://m2.mtmt.hu/api/publication/34314284},
	author = {Liu, S.V. and Mok, T.S.K. and Nabet, B.Y. and Mansfield, A.S. and De, Boer R. and Losonczy, György and Sugawara, S. and Dziadziuszko, R. and Krzakowski, M. and Smolin, A. and Hochmair, M.J. and Garassino, M.C. and Gay, C.M. and Heymach, J.V. and Byers, L.A. and Lam, S. and Cardona, A. and Morris, S. and Adler, L. and Shames, D.S. and Reck, M.},
	doi = {10.1016/j.lungcan.2023.107418},
	journal-iso = {LUNG CANCER-J IASLC},
	journal = {LUNG CANCER},
	volume = {186},
	unique-id = {34314284},
	issn = {0169-5002},
	year = {2023},
	eissn = {1872-8332},
	orcid-numbers = {Losonczy, György/0000-0002-5340-360X}
}

@article{MTMT:34214284,
	title = {Deszaturációhoz és tudatzavarhoz vezető súlyos dinamikus hiperinfláció vagy asthmás roham bronchiectasiában?},
	url = {https://m2.mtmt.hu/api/publication/34214284},
	author = {Vámos, Melinda and Kolozsvári, Dóra and Varga, János Tamás and Müller, Veronika and Losonczy, György},
	journal-iso = {REHABILITÁCIÓ},
	journal = {REHABILITÁCIÓ: A MAGYAR REHABILITÁCIÓS TÁRSASÁG FOLYÓIRATA},
	volume = {33},
	unique-id = {34214284},
	issn = {0866-479X},
	year = {2023},
	pages = {157-157},
	orcid-numbers = {Vámos, Melinda/0000-0001-8653-7500; Varga, János Tamás/0000-0002-8552-1336; Müller, Veronika/0000-0002-1398-3187; Losonczy, György/0000-0002-5340-360X}
}

@article{MTMT:34214276,
	title = {Sikeres fizioterápia extrém mértékű és fulladásos rohamhoz is vezető nyugalmi hiperinflációban öröklött bronchiectasiás fiatalemberben},
	url = {https://m2.mtmt.hu/api/publication/34214276},
	author = {Kolozsvári, Dóra and Vámos, Melinda and Varga, János Tamás and Müller, Veronika and Losonczy, György},
	journal-iso = {REHABILITÁCIÓ},
	journal = {REHABILITÁCIÓ: A MAGYAR REHABILITÁCIÓS TÁRSASÁG FOLYÓIRATA},
	volume = {33},
	unique-id = {34214276},
	issn = {0866-479X},
	year = {2023},
	pages = {135-135},
	orcid-numbers = {Vámos, Melinda/0000-0001-8653-7500; Varga, János Tamás/0000-0002-8552-1336; Müller, Veronika/0000-0002-1398-3187; Losonczy, György/0000-0002-5340-360X}
}

@article{MTMT:34162695,
	title = {A bakteriális lizátum OM-85 hatása ismétlődő légúti fertőzésekben, asthma bronchiale-ban és COPD-ben},
	url = {https://m2.mtmt.hu/api/publication/34162695},
	author = {Losonczy, György},
	journal-iso = {MED THORAC (BP)},
	journal = {MEDICINA THORACALIS (BUDAPEST)},
	volume = {76},
	unique-id = {34162695},
	issn = {0238-2571},
	year = {2023},
	pages = {163-166},
	orcid-numbers = {Losonczy, György/0000-0002-5340-360X}
}

@CONFERENCE{MTMT:34025076,
	title = {A 6-perces sétateszt javulásának összefüggése a funkcionális és életminőség paraméterekkel a poszt-COVID rehabilitációban},
	url = {https://m2.mtmt.hu/api/publication/34025076},
	author = {Kolozsvári, D and Pintér, R and Szőllősi, Gergő József and Kup, KA and Szarvas, Zsófia and Fekete, Mónika and Jáky-Kováts, Zsuzsanna Ágnes and Horváth, Gábor and Losonczy, György and Müller, Veronika and Varga, János Tamás},
	booktitle = {MTT PULMO 2023},
	unique-id = {34025076},
	year = {2023},
	pages = {76-77},
	orcid-numbers = {Szarvas, Zsófia/0000-0002-0022-5053; Fekete, Mónika/0000-0001-8632-2120; Jáky-Kováts, Zsuzsanna Ágnes/0000-0001-6145-6595; Horváth, Gábor/0000-0003-4079-1698; Losonczy, György/0000-0002-5340-360X; Müller, Veronika/0000-0002-1398-3187; Varga, János Tamás/0000-0002-8552-1336}
}

@article{MTMT:33999296,
	title = {Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers},
	url = {https://m2.mtmt.hu/api/publication/33999296},
	author = {Lazar, Jozsef and Antal-Szalmás, Péter and Kurucz, Istvan and Ferenczi, Annamaria and Józsi, Mihály and Tornyi, Ilona and Muller, Monika and Fekete, János Tibor and Lamont, John and FitzGerald, Peter and Gall-Debreceni, Anna and Kádas, János and Vida, András and Tardieu, Nadege and Kieffer, Yann and Jullien, Anne and Guergova-Kuras, Mariana and Hempel, William and Kovacs, Andras and Kardos, Tamas and Bittner, Nóra and Csanky, Eszter and Szilasi, Mária and Losonczy, György and Szondy, Klára and Gálffy, Gabriella and Csada, Edit and Szalontai, Klára Margit and Somfay, Attila and Malka, David and Cottu, Paul and Bogos, Krisztina and Takacs, Laszlo},
	doi = {10.1016/j.mcpro.2023.100580},
	journal-iso = {MOL CELL PROTEOMICS},
	journal = {MOLECULAR & CELLULAR PROTEOMICS},
	volume = {22},
	unique-id = {33999296},
	issn = {1535-9476},
	year = {2023},
	eissn = {1535-9484},
	orcid-numbers = {Lazar, Jozsef/0000-0001-7337-3682; Józsi, Mihály/0000-0002-5520-5535; Fekete, János Tibor/0000-0002-6672-6563; Losonczy, György/0000-0002-5340-360X; Szondy, Klára/0000-0002-3717-3293; Somfay, Attila/0000-0001-5062-8152; Malka, David/0000-0002-7664-0130; Takacs, Laszlo/0000-0003-1764-2096}
}

@misc{MTMT:33925652,
	title = {A BMI és a túlélési idő közötti összefüggés korai stádiumú NSCLC-ben},
	url = {https://m2.mtmt.hu/api/publication/33925652},
	author = {Szűcs, Gergő and Szentkereszty, Márton and Tóvári, István and Ladányi, Andrea and Gálffy, Gabriella and Losonczy, György},
	unique-id = {33925652},
	year = {2023},
	orcid-numbers = {Szűcs, Gergő/0000-0002-3446-0406; Szentkereszty, Márton/0000-0001-8891-8657; Ladányi, Andrea/0000-0001-9304-8473; Losonczy, György/0000-0002-5340-360X}
}

@article{MTMT:33861253,
	title = {The link between the sphingolipid rheostat and obstructive sleep apnea},
	url = {https://m2.mtmt.hu/api/publication/33861253},
	author = {Horváth, Péter and Büdi, Lilla and Hammer, Dániel and Varga, R. and Losonczy, György and Tárnoki, Ádám Domonkos and Tárnoki, Dávid László and Mészáros, M. and Bikov, András},
	doi = {10.1038/s41598-023-34717-4},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {13},
	unique-id = {33861253},
	issn = {2045-2322},
	abstract = {Chronic inflammation induced by hypoxia during sleep is an important mechanism of microvascular damage in OSA patients. In this study, we investigated the role of the sphingosine rheostat, which has diverse inflammatory effects. Thirty-seven healthy subjects and 31 patients with OSA were recruited. We collected data on demographics and comorbidities. Plasma sphingosine-1-phosphate and ceramide antibody concentrations were measured by ELISA. The results were compared between the OSA and control groups, and the correlations between these measurements and markers of disease severity and comorbidities were explored. Ceramide antibody levels were significantly elevated in OSA patients (892.17 ng/ml) vs. controls (209.55 ng/ml). S1P levels were also significantly higher in patients with OSA (1760.0 pg/ml) than in controls (290.35 pg/ml, p < 0.001). The ceramide antibody concentration showed correlations with BMI (ρ = 0.25, p = 0.04), CRP (ρ = 0.36, p = 0.005), AHI (ρ = 0.43, p < 0.001), ODI (ρ = 0.43, p < 0.001), TST90% (ρ = 0.35, p = 0.004) and the lowest oxygen saturation (ρ = 0.37, p = 0.001) in the whole study population but not when patients with OSA were analyzed separately. The elevated ceramide antibody and sphingosine-1-phosphate concentrations in patients suffering from OSA suggests their involvement in the pathomechanism of OSA and its comorbidities. © 2023, The Author(s).},
	year = {2023},
	eissn = {2045-2322},
	orcid-numbers = {Losonczy, György/0000-0002-5340-360X; Tárnoki, Ádám Domonkos/0000-0001-5909-3780; Tárnoki, Dávid László/0000-0002-7001-7647; Bikov, András/0000-0002-8983-740X}
}